Oncology remains the undisputed leader in global dealmaking for 2025, fueled by relentless demand for differentiated therapies and next-generation modalities.

Innoplexus’ CTP model forecasts the outcome of clinical studies and may serve as an early indicator for future stock movements.

Gene therapy promises to hold the cure to a number of diseases which, until now, have been considered incurable. Read our recent whitepaper: Advancements in gene therapy – usage of AAV vectors here.

Emergence of chimeric antigen receptor-t (CAR-T) cell therapies for cancer treatment.

Big Pharma M&As are driven by premium platform technologies, neurology, oncology and obesity bets and near-term readouts that will validate the deals.